Skip to main content

Table 3 List of excluded studies at full text screening with reasons. The following studies were excluded during screening of full text papers as they did not meet the eligibility criteria for the reasons listed below

From: Deprescribing psychotropic medicines for behaviours that challenge in people with intellectual disabilities: a systematic review

IPP

Incorrect Patient Population

IO

Incorrect Outcome

II

Incorrect Intervention

FTPU

Full Text Paper Unavailable

EXCLUDED STUDY

REASON FOR EXCLUSION

Alblowi, M. A., and F. D. Alosaimi. “Tardive Dyskinesia Occurring in a Young Woman after Withdrawal of an Atypical Antipsychotic Drug.” Neurosciences 20.4 (2015): 376–79.

IPP

Baglio, Christopher. “Evidence and Impact of Expectancies Associated with Psychotropic Medication Reductions in Persons with Mental Retardation.” ED.D.Dissertations. 15. (2010).

IO

Branford, D. “Antipsychotic Drugs in Learning Disabilities (Mental Handicap).” Pharmaceutical Journal 258.6936 (1997): 451–56.

II

Briggs, R. “Monitoring and Evaluating Psychotropic Drug Use for Persons with Mental Retardation: A Follow-up Report.” American Journal of Mental Retardation 93.6 (1989): 633–9.

FTPU

Campbell, M., et al. “Tardive and Withdrawal Dyskinesia in Autistic Children: A Prospective Study.” Psychopharmacology Bulletin 24.2 (1988): 251–55.

FTPU

Campbell, M., et al. “Neuroleptic-Related Dyskinesias in Autistic Children: A Prospective, Longitudinal Study.” Journal of the American Academy of Child & Adolescent Psychiatry 36.6 (1997): 835–43.

IPP

Connor, D. F., S. Benjamin, and K. R. Ozbayrak. “Case-Study - Neuroleptic Withdrawal Dyskinesia Exacerbated by Ongoing Stimulant Treatment.” Journal of the American Academy of Child and Adolescent Psychiatry 34.11 (1995): 1490–94.

IPP

Connor, D. F., and T. J. McLaughlin. “A Naturalistic Study of Medication Reduction in a Residential Treatment Setting.” Journal of Child & Adolescent Psychopharmacology 15.2 (2005): 302–10.

IPP

Davies, S. J., et al. “Discontinuation of Thioridazine in Patients with Learning Disabilities: Balancing Cardiovascular Toxicity with Adverse Consequences of Changing Drugs.” BMJ 324.7352 (2002): 1519–21.

IPP

Deb, S., and W. Fraser. “The Use of Psychotropic Medication in People with Learning Disability: Towards Rational Prescribing.” Human Psychopharmacology 9.4 (1994): 259–72.

II

Deb, S., G. Unwin, and T. Deb. “Characteristics and the Trajectory of Psychotropic Medication Use in General and Antipsychotics in Particular among Adults with an Intellectual Disability Who Exhibit Aggressive Behaviour.” Journal of Intellectual Disability Research 59.1 (2015): 11–25.

II

Granas, A. G., et al. “Interdisciplinary Medication Review to Improve Pharmacotherapy for Patients with Intellectual Disabilities.” International Journal of Clinical Pharmacy 41.6 (2019): 1516–25.

II

Hancock, Robert D., et al. “Changes in Psychotropic Drug Use in Long-Term Residents of an Icf/Mr Facility.” American Journal on Mental Retardation 96.2 (1991): 137–41.

II

Malone, R. P., et al. “Repeated Episodes of Neuroleptic-Related Dyskinesias in Autistic Children.” Psychopharmacology Bulletin 27.2 (1991): 113–7.

FTPU

Malone, R. P., et al. “Risperidone Treatment in Children and Adolescents with Autism: Short- and Long-Term Safety and Effectiveness.” Journal of the American Academy of Child & Adolescent Psychiatry 41.2 (2002): 140–7.

IO

Okorie, E., and C. Connaughton. “Antipsychotic Prescribing in a Residential Facility for Clients with Learning Disabilty.” British Journal of Developmental Disabilities 57.2 (2011): 11722.

II

Perez, C. A., S. S. Garcia, and R. D. Yu. “Extrapyramidal Symptoms as a Result of Risperidone Discontinuation During Combination Therapy with Methylphenidate in a Pediatric Patient.” Journal of Child and Adolescent Psychopharmacology 26.2 (2016): 182.

IPP

Silva, R. R., et al. “Haloperidol Withdrawal and Weight Changes in Autistic Children.” Psychopharmacology Bulletin 29.2 (1993): 287–91.

FPTU

Sovner, R. “Thioridazine Withdrawal-Induced Behavioral Deterioration Treated with Clonidine: Two Case Reports.” Mental Retardation 33.4 (1995): 221–5

IPP

Tiihonen, Jari. “Fatal Agranulocytosis 4 Years after Discontinuation of Clozapine.” The American Journal of Psychiatry 163.1 (2006): 161.

II

Wrein, D. “Understanding the Role of Care Staff in Supporting Individuals with an Intellectual Disability Who Take Psychotropic Medication.” Prof Doc Thesis University of East London School of Psychology (2019).

IO